Merck KGaA, Darmstadt, Germany, said the FDA has granted Breakthrough Therapy designation to enpatoran for the treatment of lupus in patients with active cutaneous manifestations.
Enpatoran is an investigational oral selective toll‑like receptor 7/8 inhibitor designed to modulate immune pathways implicated in lupus‑related inflammation. The designation is intended to expedite development and review in serious conditions where early clinical data suggest a potential improvement over available therapies.
The FDA’s decision is supported by results from the Phase 2 WILLOW trial, a multicenter, randomized, double‑blind, placebo‑controlled dose‑finding study that enrolled patients with cutaneous lupus erythematosus and systemic lupus erythematosus. In the study, enpatoran produced clinically meaningful improvements in lupus symptoms, with particularly notable effects in patients with active skin involvement.
Lupus is a chronic autoimmune disease that can affect the skin, joints, kidneys, and central nervous system. Skin manifestations—often inflamed, photosensitive lesions on the face, scalp, and other areas—are reported in the majority of patients and can significantly affect quality of life. For many, current treatment options do not provide adequate, sustained control of cutaneous disease.
Merck KGaA has recently launched ELOWEN 1 and ELOWEN 2, a global Phase 3 program evaluating enpatoran’s effects on both cutaneous and systemic manifestations of lupus and exploring links between skin activity and broader disease control.
Enpatoran remains in clinical development and is not approved for use in any country.
Subscribe to our e-Newsletters
Stay up to date with the latest news, articles, and events. Plus, get special offers
from American Pharmaceutical Review – all delivered right to your inbox!
Sign up now!